Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases

Breye Therapeutics (Breye), a Danish clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, has closed an oversubscribed €67.5 million Series A financing round. The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new…

Danish biotech firm Breye Therapeutics has secured €67.5 million in Series A funding to advance its oral therapies for early treatment of retinal diseases. The round was co-led by Mission BioCapital and Novo Holdings, with support from existing investor Sound Bioventures and other new investors. Breye's CEO Ulrik Mouritzen praised the financing, stating it reflects strong confidence in the company's vision and pipeline.

The funding will enable Breye to advance danegaptide, a pioneering oral treatment for diabetic retinopathy, into the next stage of clinical development. Diabetic retinopathy affects about 130 million people worldwide and is a leading cause of vision loss in working-age adults. The company's lead candidate, danegaptide, is a first-in-class oral small molecule with a novel mechanism of action that stabilizes retinal vasculature and protects against retinal capillary breakdown.

Breye plans to use the capital to progress danegaptide into a randomized Phase 2 clinical trial, which is scheduled to begin in 2027, as well as to support its broader pipeline of oral small molecules targeting eye diseases such as intermediate age-related macular degeneration, glaucoma, and other indications.

Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at eu-startups.com →

More in Health & Medicine

More from Friday 2 October →